{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:41:35Z","timestamp":1760784095987,"version":"3.41.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T00:00:00Z","timestamp":1452038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Medical University of Lublin","doi-asserted-by":"crossref","award":["473\/15"],"award-info":[{"award-number":["473\/15"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s11064-015-1812-x","type":"journal-article","created":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T06:07:39Z","timestamp":1452060459000},"page":"1185-1191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mexiletine and its Interactions with Classical Antiepileptic Drugs: An Isobolographic Analysis"],"prefix":"10.1007","volume":"41","author":[{"given":"Kinga K.","family":"Borowicz-Reutt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Banach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Piskorska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,6]]},"reference":[{"key":"1812_CR1","doi-asserted-by":"crossref","unstructured":"Wang Y, Mi J, Lu K, Lu Y, Wang K (2015) Comparison of gating properties and use- dependent block of Nav1.5 and Nav1.7 channels by anti-arrhythmics mexiletine and lidocaine. PLoS One. doi: 10.1371\/journal.pone.0128653","DOI":"10.1371\/journal.pone.0128653"},{"key":"1812_CR2","first-page":"231","volume":"8","author":"GJ Alexander","year":"1986","unstructured":"Alexander GJ, Kopeloff LM, Alexander RB, Chatterjie N (1986) Mexiletine: biphasic action on convulsive seizures in rodents. Neurobehav Toxicol Teratol 8:231\u2013235","journal-title":"Neurobehav Toxicol Teratol"},{"key":"1812_CR3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0006-8993(02)02275-8","volume":"932","author":"AJ Williams","year":"2002","unstructured":"Williams AJ, Tortella FC (2002) Neuroprotective effects of the sodium channel blocker RS100642 and attenuation of ischemia-induced brain seizures in the rat. Brain Res 932:45\u201355","journal-title":"Brain Res"},{"key":"1812_CR4","first-page":"29","volume":"32","author":"H Enoki","year":"2000","unstructured":"Enoki H, Hata H, Ohmori I, Maniwa S, Ohta H, Kobayashi K (2000) Clinical applications and the effect of mexiletine on refractory epilepsies. No To Hattatsu 32:29\u201334","journal-title":"No To Hattatsu"},{"key":"1812_CR5","first-page":"459","volume":"31","author":"A Miyamoto","year":"1999","unstructured":"Miyamoto A, Takahashi S, Oki J (1999) A successful treatment with intravenous lidocaine followed by oral mexiletine in a patient with Lennox-Gastaut syndrome. No To Hattatsu 31:459\u2013464","journal-title":"No To Hattatsu"},{"key":"1812_CR6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.braindev.2012.10.011","volume":"35","author":"M Nakazawa","year":"2013","unstructured":"Nakazawa M, Okumura A, Niijima S, Yamashita S, Shimono K, Hirose S, Shimizu T (2013) Oral mexiletine for lidocaine-responsive neonatal epilepsy. Brain Dev 35:667\u2013669","journal-title":"Brain Dev"},{"key":"1812_CR7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/mf.2009.31.2.1338414","volume":"31","author":"MM Castel-Branco","year":"2009","unstructured":"Castel-Branco MM, Alves GL, Figueiredo IV, Falc\u00e3o AC, Caramona MM (2009) The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drug. Methods Find Exp Clin Pharmacol 31:101\u2013106","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"1812_CR8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-007-0878-9","volume":"195","author":"KK Borowicz","year":"2007","unstructured":"Borowicz KK, Banach M, Zarczuk R, \u0141ukasik D, \u0141uszczki JJ, Czuczwar SJ (2007) Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model. Psychopharmacology 195:167\u2013174","journal-title":"Psychopharmacology"},{"key":"1812_CR9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","volume":"96","author":"JT Litchfield","year":"1949","unstructured":"Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99\u2013113","journal-title":"J Pharmacol Exp Ther"},{"key":"1812_CR10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000134913","volume":"3","author":"JR Boissier","year":"1960","unstructured":"Boissier JR, Tardy J, Diverres JC (1960) Une nouvelle methode simple pour explorer l\u2019action tranquilisante: le test de la cheminee. Med Exp (Basel) 3:81\u201384","journal-title":"Med Exp (Basel)"},{"key":"1812_CR11","doi-asserted-by":"crossref","DOI":"10.1201\/9781420036107","volume-title":"Drug synergism and dose-effect data analysis","author":"RJ Tallarida","year":"2000","unstructured":"Tallarida RJ (2000) Drug synergism and dose-effect data analysis. Chapton & Hall, Boca Raton"},{"key":"1812_CR12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0014-2999(90)90190-H","volume":"179","author":"F Porreca","year":"1990","unstructured":"Porreca F, Jiang Q, Tallarida RJ (1990) Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur J Pharmacol 179:463\u2013468","journal-title":"Eur J Pharmacol"},{"key":"1812_CR13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1046\/j.1528-1157.2002.34301.x","volume":"43","author":"KK Borowicz","year":"2002","unstructured":"Borowicz KK, Swiader M, Luszczki J, Czuczwar SJ (2002) Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia 43:956\u2013963","journal-title":"Epilepsia"},{"key":"1812_CR14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1528-1157.2003.32702.x","volume":"44","author":"JJ Luszczki","year":"2003","unstructured":"Luszczki JJ, Borowicz KK, Swiader M, Czuczwar SJ (2003) Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44:489\u2013499","journal-title":"Epilepsia"},{"key":"1812_CR15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00210-004-0867-z","volume":"369","author":"JJ Luszczki","year":"2004","unstructured":"Luszczki JJ, Czuczwar SJ (2004) Isobolographic profile of interaction between tiagabine and gabapentin: a preclinical study. Naunyn Schmiedeberg\u2019s Arch Pharmacol 369:434\u2013446","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"1812_CR16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0920-1211(91)90062-K","volume":"8","author":"W L\u00f6scher","year":"1991","unstructured":"L\u00f6scher W, Fassbender CP, Nolting B (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. Epilepsy Res 8:171\u2013189","journal-title":"Epilepsy Res"},{"key":"1812_CR17","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2165\/00003495-199040030-00005","volume":"40","author":"JP Monk","year":"1990","unstructured":"Monk JP, Brogden RN (1990) Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs 40:374\u2013411","journal-title":"Drugs"},{"key":"1812_CR18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3109\/15563659409017980","volume":"32","author":"LS Nelson","year":"1994","unstructured":"Nelson LS, Hoffman RS (1994) Mexiletine overdose producing status epilepticus without cardiovascular abnormalities. J Toxicol Clin Toxicol 32:731\u2013736","journal-title":"J Toxicol Clin Toxicol"},{"key":"1812_CR19","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","volume":"41","author":"CL Deckers","year":"2000","unstructured":"Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN, Renier WO, Van Rijn CM (2000) Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41:1364\u20131374","journal-title":"Epilepsia"},{"key":"1812_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-1211(02)00257-7","volume":"53","author":"CL Deckers","year":"2003","unstructured":"Deckers CL, Genton P, Sills GJ, Schmidt D (2003) Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res 53:1\u201317","journal-title":"Epilepsy Res"},{"key":"1812_CR21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0165-0173(97)00054-4","volume":"26","author":"DS Ragsdale","year":"1998","unstructured":"Ragsdale DS, Avoli M (1998) Sodium channels as molecular targets for antiepileptic drugs. Brain Res Rev 26:16\u201328","journal-title":"Brain Res Rev"},{"key":"1812_CR22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00023210-200115050-00001","volume":"15","author":"SJ Czuczwar","year":"2001","unstructured":"Czuczwar SJ, Patsalos PN (2001) The new generation of GABA enhancers. CNS Drugs 15:339\u2013350","journal-title":"CNS Drugs"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-015-1812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-015-1812-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-015-1812-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T01:56:40Z","timestamp":1748743000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-015-1812-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,6]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["1812"],"URL":"https:\/\/doi.org\/10.1007\/s11064-015-1812-x","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"type":"print","value":"0364-3190"},{"type":"electronic","value":"1573-6903"}],"subject":[],"published":{"date-parts":[[2016,1,6]]}}}